Abstract
The rising disease burden and high price of new oncology medicines, combined with uncertainty in clinical and economic evidence, have brought substantial challenges to payers and health technology assessment (HTA) in making decisions on coverage. This review intended to comprehensively summarize the significant predictors and their relative importance in HTA decisions for cancer drugs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
